James Harding MD

Clinical Trials

• A Study of LY2157299 in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Mar 30

  Completed

  Phase 2

• Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Start of enrollment: 2014 Feb 01

  Completed

  Phase 1

• A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Start of enrollment: 2014 Mar 07

  Completed

  Phase 1, Phase 2

• Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma Start of enrollment: 2014 Nov 01

  Terminated

  Phase 1, Phase 2

• Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2014 Aug 07

  Terminated

  Phase 1

• An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Start of enrollment: 2015 Dec 07

  COMPLETED

  PHASE3

• Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients Start of enrollment: 2015 Dec 01

  Completed

  Phase 1

• PF-06671008 Dose Escalation Study in Advanced Solid Tumors Start of enrollment: 2016 Apr 28

  Terminated

  Phase 1

• A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors Start of enrollment: 2016 Jun 20

  Completed

  Phase 1, Phase 2

• A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors Start of enrollment: 2017 Apr 12

  Completed

  Phase 1

• A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer Start of enrollment: 2017 Apr 28

  ACTIVE_NOT_RECRUITING

  EARLY_PHASE1

• An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Start of enrollment: 2017 May 25

  Terminated

  Phase 1

• Study of GNS561 in Patients With Liver Cancer Start of enrollment: 2018 Apr 04

  Terminated

  Phase 1, Phase 2

• YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) Start of enrollment: 2020 Jan 10

  COMPLETED

  PHASE2

• A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer Start of enrollment: 2020 Mar 11

  COMPLETED

  PHASE1

• A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers Start of enrollment: 2020 Oct 01

  COMPLETED

  PHASE2

• Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Start of enrollment: 2020 Oct 01

  ACTIVE_NOT_RECRUITING

  PHASE1

• PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors Start of enrollment: 2017 Jun 01

  Terminated

  Phase 1, Phase 2

• A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC) Start of enrollment: 2022 Jun 28

  Terminated

  Phase 1

• A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer Start of enrollment: 2022 May 05

  ACTIVE_NOT_RECRUITING

  PHASE1, PHASE2

• A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations Start of enrollment: 2022 Mar 29

  TERMINATED

  PHASE1

  Roles: Contact

• Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Start of enrollment: 2022 Dec 13

  ACTIVE_NOT_RECRUITING

  PHASE2

• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 Start of enrollment: 2023 Nov 09

  RECRUITING

  PHASE1

• A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma Start of enrollment: 2023 Mar 23

  RECRUITING

  PHASE1, PHASE2

• Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer Start of enrollment: 2024 Jul 19

  RECRUITING

  PHASE3

• Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) Start of enrollment: 2023 Dec 04

  RECRUITING

  PHASE3

• Join now to see all